Recent advances in structure-guided drug discovery have already yielded promising lead compounds demonstrating selective recognition of C9orf72 G4 structures, which is significant for developing targeted therapies for ALS/FTD [27]. Here, C9orf72 is linked to frontotemporal dementia.